Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 7/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727220 | 0.82 | CYP2C19 (0.50) | CETPCYP2C19MMEALDH1A1SMN1; SMN2 | |
| SCHEMBL810162 | 0.82 | CETP (0.49) | CETPCYP2C19MME | |
| SCHEMBL9974581 | 0.81 | CETP (0.48) | CETPCYP2C19MME | |
| SCHEMBL9971636 | 0.81 | CETP (0.48) | CETPCYP2C19MME | |
| SCHEMBL1534074 | 0.81 | CETP (0.48) | CETPCYP2C19MME | |
| SCHEMBL11381051 | 0.80 | CYP2C19 (0.38) | CETPCYP2C19MMEALDH1A1SMN1; SMN2 | |
| SCHEMBL2203045 | 0.79 | CETP (0.47) | CETPCYP2C19MME | |
| SCHEMBL9524739 | 0.78 | CYP2C19 (0.36) | CETPCYP2C19MMEALDH1A1SMN1; SMN2 | |
| SCHEMBL9972631 | 0.78 | CETP (0.47) | CETPCYP2C19MME | |
| SCHEMBL1421653 | 0.78 | CETP (0.49) | CETPCYP2C19MMEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1635911-A | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER PROD INC (US) | 2005-07-06 | — | — | CN | claimed |
| EP-1305007-A2 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | claimed |
| WO-2002011710-A2 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-02-14 | — | — | WO | claimed |
| CN-107011148-A | Method for preparing naphthenic acid | 霍夫曼-拉罗奇有限公司 | 2017-08-04 | — | — | CN | disclosed |
| US-9603816-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603816-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2274278-B1 | NEW PROCESS FOR THE PREPARATIION OF CYCLOHEXANECARBOXYLIC ACID DERICATIVES | HOFFMANN LA ROCHE (CH) | 2016-08-17 | — | — | EP | disclosed |
| EP-2274278-B1 | NEW PROCESS FOR THE PREPARATIION OF CYCLOHEXANECARBOXYLIC ACID DERICATIVES | HOFFMANN LA ROCHE (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160200672-A1 | NEW PROCESS | HOFFMANN-LA ROCHE INC. | 2016-07-14 | — | — | US | disclosed |
| US-20150361034-A1 | NEW PROCESS | HOFFMANN-LA ROCHE INC. | 2015-12-17 | — | — | US | disclosed |
| EP-2616433-B1 | PROCESS FOR PREPARING A CYCLOHEXANECARBONITRILE DERIVATIVE | HOFFMANN LA ROCHE (CH) | 2015-12-09 | — | — | EP | disclosed |
| CN-1625397-A | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | PFIZER PROD INC (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1545421-A | Pharmaceutical composition comprising a low-solubility and/or acid-sensitive drug and a neutralized acidic polymer | �Ʒ� | 2004-11-10 | — | — | CN | disclosed |
| EP-1469831-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID AMORPHOUS DISPERSION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| CN-1523979-A | Pharmaceutical compositions of adsorbates of amorphous drug | �Ʒ� | 2004-08-25 | — | — | CN | disclosed |
| EP-1401399-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003063832-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID AMORPHOUS DISPERSION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1305007-A2 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003000226-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002011710-A2 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200672-A1 | NEW PROCESS | CYP4A11, UGT1A1, CYP11B1 | CETP 565/4885CYP2C19 16/4885MME 1044/4885 |
| US-20150361034-A1 | NEW PROCESS | CYP4A11, UGT1A1, CYP11B1 | CETP 565/4885CYP2C19 16/4885MME 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.